Non-Small Cell Lung Cancer Archives

Immunotherapy May Increase the Risk of Treatment Discontinuation in SCLC

By

Leah Lawrence

March 24, 2023

Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.

This frontal view x-ray of the chest shows advanced stage non-small cell lung cancer (NSCLC) of a 50-year-old woman with a long history of smoking and emphysema. The orange area depicts collapsed lung tissue at the base of the right lung, and the yellow area highlights a pleura-based density along the right hemithorax.

ONA Summit 2023

Updates in Targeted Therapies, Management Strategies for Non-Small Cell Lung Cancer

By

Marianne Davies, DNP, ACNP, AOCNP

March 17, 2023

In an oral presentation at the 2023 ONA Summit, a thoracic oncology nurse practitioner reviewed the advances in the treatment of NSCLC and management of related adverse effects.

Lung Cancer

Pembrolizumab Improves 5-Year PFS, OS in Metastatic NSCLC

By

Leah Lawrence

March 8, 2023

Five-year data support the use of pembrolizumab plus pemetrexed-platinum chemotherapy as standard care for previously untreated, metastatic, EGFR/ALK-wild-type NSCLC, according to researchers.

Lung Cancer

Chemotherapy Improves Outcomes in EFGR-Mutated NSCLC With Brain Metastases

By

Andrea S. Blevins Primeau, PhD, MBA

February 22, 2023

Adding chemotherapy to first-line treatment with gefitinib improves outcomes in patients who have EGFR-mutant non-small cell lung cancer with brain metastases, a phase 3 trial suggests.

Lung Cancer

Sublobar Resection Not Inferior to Lobar Resection for T1aN0 NSCLC

February 14, 2023

Sublobar resection is noninferior for disease-free and overall survival for patients with tumors ≤2 cm.

Lung Cancer

Targeted Therapies for Non-Small Cell Lung Cancer Underused in Patients on Medicaid

By

Andrea S. Blevins Primeau, PhD, MBA

January 31, 2023

Targeted therapies are underused in Medicaid patients with EGFR- or ALK-altered, metastatic non-small cell lung cancer, research suggests.

Lung Cancer

High TMB Predicts Better Outcomes of Chemoradiation Plus Durvalumab in NSCLC

By

Leah Lawrence

January 19, 2023

Tumor mutational burden can predict outcomes of chemoradiation plus durvalumab in patients with stage III non-small cell lung cancer, a study suggests.

Lung Cancer

Domvanalimab-Containing Regimens Show Activity in PD-L1-High NSCLC

By

Leah Lawrence

January 3, 2023

Domvanalimab-containing treatment regimens may improve outcomes, when compared with zimberelimab alone, in patients with PD-L1-high non-small cell lung cancer.